Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda, commonly known as Azidus Brasil or simply AZD, is a Brazilian contract research organization (CRO) headquartered in Valinhos, in the state of São Paulo, with an additional office in the city of São Paulo. The company positions itself as a full-service clinical research partner, offering services and solutions designed to accelerate the execution of clinical studies and the registration of pharmaceutical, biological and related health products. According to its official website, AZD CRO provides end-to-end services covering all processes involved in clinical development, from the earliest stages — proof-of-concept studies, First-in-Human trials, Phase I and drug-interaction studies — through to the later phases, including Phase IV post-marketing studies. The company states that it has 25 years of experience in the global market and emphasizes efficient, high-quality solutions delivered within timelines suited to market needs. It highlights regulatory expertise and speed as distinguishing characteristics, with the claim that "at AZD your clinical trial starts earlier." Azidus Brasil operates from its headquarters in Valinhos-SP and an office in São Paulo, and it extends its reach through strategic partnerships in Argentina, Colombia, Uruguay, Mexico, Canada, the United States, Israel and Eastern Europe. The company says its experienced team provides the technical and regulatory capability to meet the requirements of major regulatory agencies worldwide, including the FDA (United States), EMEA (Europe), Health Canada, ANVISA (Brazil), ANMAT (Argentina), INVIMA (Colombia) and COFEPRIS (Mexico). Leadership listed on the company's website includes Dra. Luciana Ferrara as CEO, Paulo Fernandes as Chief Operating Officer, Tânia Pinheiro as Project Operations Director, Josiane Fazio as Project and B&D Manager, and Dr. Eduardo Pagani as Medical Writing Director. The company is privately held and is not known to be listed on a public stock exchange. Its service portfolio and partnership network make it a participant in Brazil's clinical research and pharmaceutical development services sector, serving sponsors that need local and multi-country trial execution and regulatory submission support.

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda is a Brazilian clinical research and development company based in Valinhos, São Paulo. Public information about the company is limited, but its official website provides the clearest picture of its identity and activities. The company operates under the short brand name AZD and presents itself as a contract research organization (CRO) under the label "AZD CRO." According to its website, the company states that it has 25 years of experience in the global market. This claim, as published by the company, indicates a long-standing presence in clinical research services, although the exact founding year is not specified in the available evidence. The company's headquarters are located in Valinhos-SP, and it maintains an office in the city of São Paulo. Azidus Brasil describes its core activity as offering services and solutions to accelerate the execution of clinical studies and the registration of products. Its service structure is presented as end-to-end, covering all processes involved in clinical development. This ranges from the conception of studies in the earliest phases — proof-of-concept studies, First-in-Human trials, Phase I and drug-interaction studies — through to the later phases, including Phase IV studies. The company emphasizes regulatory expertise and speed as key differentiators. It states that it is recognized for its regulatory expertise and the speed of its processes, with the message that "at AZD your clinical trial starts earlier." To support multi-country trials, Azidus Brasil operates through strategic partnerships in Argentina, Colombia, Uruguay, Mexico, Canada, the United States, Israel and Eastern Europe. Its team is described as experienced, providing the technical and regulatory capability to meet the requirements of major global regulatory agencies, including the FDA, EMEA, Health Canada, ANVISA, ANMAT, INVIMA and COFEPRIS. Leadership information published on the company's website identifies Dra. Luciana Ferrara as CEO, Paulo Fernandes as Chief Operating Officer, Tânia Pinheiro as Project Operations Director, Josiane Fazio as Project and B&D Manager, and Dr. Eduardo Pagani as Medical Writing Director. The company is privately held. No public listing, major ownership changes, acquisitions or other corporate milestones are documented in the available evidence.

Full-service Brazilian CRO emphasizing regulatory expertise, speed and end-to-end clinical development support from early-phase to Phase IV studies.

• AZD CRO end-to-end clinical research services

  Services and solutions covering all processes involved in clinical development, from early-phase studies to Phase IV.

• Early-phase clinical studies

  Proof-of-concept studies, First-in-Human trials, Phase I and drug-interaction studies.

• Late-phase clinical studies

  Phase IV post-marketing studies.

• Regulatory affairs and submission support

  Regulatory expertise to meet requirements of FDA, EMEA, Health Canada, ANVISA, ANMAT, INVIMA and COFEPRIS.

• Medical writing

  Medical writing services led by a dedicated Medical Writing Director.

1. 1Azidus | azidusbrasilazidusbrasil.com.br
2. 2Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda (Brazil) - Wikidatawikidata.org